MedTrace Logo

Glucose Absorption and Gut Hormone Secretion After Gastric Bypass

NCT03426956 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-02-09

No results posted yet for this study

Summary

To investigate the impact of canagliflozin on secretion of gut hormones, in particular glucagon-like peptide 1 (GLP-1) in gastric bypass operated patients.

Conditions

Interventions

DIETARY_SUPPLEMENT

Glucose

Ingestion of glucose (50 g) dissolved in 200 ml water.

DIETARY_SUPPLEMENT

Glucose + Canagliflozin

Ingestion of glucose (50 g) dissolved in 200 ml water combined with the SGLT-1/SGLT-2 inhibitor canagliflozin.

Sponsors & Collaborators

  • Hvidovre University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-08
Primary Completion
2019-05-01
Completion
2019-05-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03426956 on ClinicalTrials.gov